Bioventus (NYSE:BVS – Get Rating) posted its quarterly earnings results on Tuesday. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.01), MarketWatch Earnings reports. Bioventus had a return on equity of 21.93% and a net margin of 2.67%. During the same period last year, the business posted ($0.02) EPS.
Shares of BVS stock traded up $0.55 during trading on Thursday, reaching $8.04. 16,736 shares of the company’s stock were exchanged, compared to its average volume of 194,625. The company has a quick ratio of 1.11, a current ratio of 1.45 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $614.17 million, a PE ratio of -50.00 and a beta of 1.43. Bioventus has a twelve month low of $7.39 and a twelve month high of $19.94. The firm’s fifty day moving average price is $12.66 and its 200-day moving average price is $13.37.
In other Bioventus news, insider John Nosenzo sold 65,963 shares of the company’s stock in a transaction on Monday, April 4th. The stock was sold at an average price of $11.12, for a total value of $733,508.56. Following the transaction, the insider now directly owns 83,932 shares of the company’s stock, valued at approximately $933,323.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Anthony D’adamio sold 16,016 shares of the company’s stock in a transaction on Monday, April 4th. The shares were sold at an average price of $11.19, for a total value of $179,219.04. Following the completion of the transaction, the senior vice president now directly owns 148,309 shares in the company, valued at $1,659,577.71. The disclosure for this sale can be found here. Insiders have sold a total of 83,807 shares of company stock worth $934,645 over the last three months.
Several research analysts have weighed in on the company. The Goldman Sachs Group lowered their price target on Bioventus from $19.00 to $17.00 and set a “neutral” rating on the stock in a research report on Monday, March 21st. Craig Hallum assumed coverage on Bioventus in a research report on Tuesday, March 15th. They set a “buy” rating and a $30.00 price target on the stock. Morgan Stanley lowered their price target on Bioventus from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, March 11th. Finally, Zacks Investment Research lowered Bioventus from a “hold” rating to a “sell” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $21.67.
Bioventus Company Profile (Get Rating)
Bioventus Inc a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy.
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.